Skip to main content

Advertisement

Table 2 Base case results

From: Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model

Option Major bleeds/100 person-year Major TE/100 person-year Cost/patient (CAD $) QALY/patient Cost/QALY ∆ Cost CAD $ ∆ QALY ICUR
Standard warfarin* dosage 3.21 2.12 7 289 3.5368 2061    
Pharmacogenetic oriented warfarin dosage 3.09 2.126 7 749 3.5453 2186 460 0.0085 Dominated
Dabigatran 150 mg BID 2.872 1.813 8 494 3.7897 2241 745 0.2444 4 765
  1. *Less costly option.